United States - English - NLM (National Library of Medicine)

pai holdings, llc - nortriptyline hydrochloride (unii: 00fn6ih15d) (nortriptyline - unii:bl03sy4lxb) - nortriptyline 10 mg in 5 ml - nortriptyline hydrochloride oral solution is indicated for the relief of symptoms of depression. endogenous depressions are more likely to be alleviated than are other depressive states. the use of maois intended to treat psychiatric disorders with nortriptyline hydrochloride oral solution or within 14 days of stopping treatment with nortriptyline hydrochloride oral solution is contraindicated because of an increased risk of serotonin syndrome. the use of nortriptyline hydrochloride oral solution within 14 days of stopping an maoi intended to treat psychiatric disorders is also contraindicated (see warnings and dosage and administration ). starting nortriptyline hydrochloride oral solution in a patient who is being treated with maois such as linezolid or intravenous methylene blue is also contraindicated because of an increased risk of serotonin syndrome (see warnings and dosage and admini

United States - English - NLM (National Library of Medicine)

pai holdings, llc - valproic acid (unii: 614oi1z5wi) (valproic acid - unii:614oi1z5wi) - valproic acid 250 mg in 5 ml - valproic acid is indicated as monotherapy and adjunctive therapy in the treatment of patients with complex partial seizures that occur either in isolation or in association with other types of seizures. valproic acid is indicated for use as sole and adjunctive therapy in the treatment of simple and complex absence seizures, and adjunctively in patients with multiple seizure types which include absence seizures. simple absence is defined as very brief clouding of the sensorium or loss of consciousness accompanied by certain generalized epileptic discharges without other detectable clinical signs. complex absence is the term used when other signs are also present. see warnings and precautions (5.1) for statement regarding fatal hepatic dysfunction. because of the risk to the fetus of decreased iq, neurodevelopmental disorders, neural tube defects, and other major congenital malformations, which may occur very early in pregnancy, valproate should not be used to treat women with epilepsy or bipola

United States - English - NLM (National Library of Medicine)

pai holdings, llc - phenytoin (unii: 6158tkw0c5) (phenytoin - unii:6158tkw0c5) - phenytoin oral suspension is indicated for the treatment of tonic-clonic (grand mal) and psychomotor (temporal lobe) seizures. phenytoin oral suspension is contraindicated in patients with: - a history of hypersensitivity to phenytoin, its inactive ingredients, or other hydantoins [see warnings and precautions (5.5)]. reactions have included angioedema. - a history of prior acute hepatotoxicity attributable to phenytoin [see warnings and precautions (5.8)]. - coadministration with delavirdine because of the potential for loss of virologic response and possible resistance to delavirdine or to the class of non-nucleoside reverse transcriptase inhibitors. pregnancy exposure registry there is a pregnancy exposure registry that monitors pregnancy outcomes in women exposed to antiepileptic drugs (aeds), such as phenytoin, during pregnancy. physicians are advised to recommend that pregnant patients taking phenytoin enroll in the n

United States - English - NLM (National Library of Medicine)

haleon us holdings llc - diclofenac sodium (unii: qtg126297q) (diclofenac - unii:144o8ql0l1) - arthritis pain reliever - for the temporary relief of arthritis pain only in the following areas: hand, wrist, elbow (upper body areas) foot, ankle, knee (lower body areas) - hand, wrist, elbow (upper body areas) - foot, ankle, knee (lower body areas) - this product may take up to 7 days to work for arthritis pain; it is not for immediate relief. if no pain relief in 7 days, stop use. - use only as directed - do not use more than directed or for longer than directed - apply only to clean, dry skin that does not have any cuts, open wounds, infections or rashes - do not apply in same area as any other product - do not apply with external heat such as heating pad - do not apply a bandage over the treated area - store enclosed dosing card with your voltaren arthritis pain. the dosing card is re-usable.

United States - English - NLM (National Library of Medicine)

pai holdings, llc dba pai pharma - ibuprofen (unii: wk2xyi10qm) (ibuprofen - unii:wk2xyi10qm) - pain reliever/fever reducer  temporarily: - relieves minor aches and pains due to the common cold, flu, sore throat, headache and toothache - reduces fever

United States - English - NLM (National Library of Medicine)

pai holdings, llc - acetaminophen (unii: 362o9itl9d) (acetaminophen - unii:362o9itl9d) - acetaminophen 160 mg in 5 ml - pain reliever/fever reducer temporarily relieves minor aches and pains due to: - headache - muscular aches - backache - minor pain of arthritis - the common cold - toothache - premenstrual and menstrual cramps temporarily reduces fever

United States - English - NLM (National Library of Medicine)

pai holdings, llc - acetaminophen (unii: 362o9itl9d) (acetaminophen - unii:362o9itl9d) - pain reliever/fever reducer temporarily: - reduces fever - relieves minor aches and pains due to: the common cold flu headache sore throat toothache - the common cold - flu - headache - sore throat - toothache

United States - English - NLM (National Library of Medicine)

pai holdings, llc - acetaminophen (unii: 362o9itl9d) (acetaminophen - unii:362o9itl9d) - acetaminophen 160 mg.............................pain reliever/fever reducer - reduces fever - minor aches and pains due to: • the common cold • flu • headache • sore throat • toothache - with any other drug containing acetaminophen (prescription or non-prescription). if you are not sure whether a drug contains acetaminophen, ask a doctor or pharmacist. - if your child is allergic to acetaminophen or any of the inactive ingredients in this product • pain gets worse or lasts more than 5 days • fever gets worse or lasts more than 3 days • new symptoms occur • redness or swelling is present these could be signs of a serious condition.

United States - English - NLM (National Library of Medicine)

pai holdings, llc - potassium citrate (unii: ee90oni6ff) (anhydrous citric acid - unii:xf417d3psl), sodium citrate (unii: 1q73q2julr) (anhydrous citric acid - unii:xf417d3psl), citric acid monohydrate (unii: 2968phw8qp) (anhydrous citric acid - unii:xf417d3psl) - potassium citrate 550 mg in 5 ml - tricitrates sf oral solution is an effective alkalinizing agent useful in those conditions where long-term maintenance of an alkaline urine is desirable, such as in patients with uric acid and cystine calculi of the urinary tract. in addition, it is a valuable adjuvant when administered with uricosuric agents in gout therapy, since urates tend to crystallize out of an acid urine. it is also effective in correcting the acidosis of certain renal tubular disorders. this product is highly concentrated, and when administered after meals and before bedtime, allows one to maintain an alkaline urine ph around the clock, usually without the necessity of a 2 a.m. dose. this product alkalinizes the urine without producing a systemic alkalosis in recommended dosage. it is highly palatable, pleasant tasting, and tolerable, even when administered for long periods. potassium citrate and sodium citrate do not neutralize the gastric juice or disturb digestion. severe renal impairment with oliguria o

United States - English - NLM (National Library of Medicine)

pai holdings, llc - phenobarbital (unii: yqe403bp4d) (phenobarbital - unii:yqe403bp4d) - a. sedative b. anticonvulsant - for the treatment of generalized and partial seizures. phenobarbital is contraindicated in patients who are hypersensitive to barbiturates, in patients with a history of manifest or latent porphyria, and in patients with marked impairment of liver function or respiratory disease in which dyspnea or obstruction is evident. phenobarbital is a schedule iv drug. barbiturates may be habit forming. tolerance, psychological dependence, and physical dependence may occur, especially following prolonged use of high doses of barbiturates. daily administrations in excess of 400 mg of pentobarbital or secobarbital for approximately 90 days is likely to produce some degree of physical dependence. a dosage of 600 to 800 mg taken for at least 35 days is sufficient to produce withdrawal seizures. the average daily dose for the barbiturate addict is usually about 1.5 g. as tolerance to barbiturates develops, the amount needed to maintain the same level of intoxication increases; to